re: Ann: Phase II Trial in Allergic Asthma Co...
If you read between the lines it means its business as usual at Pharmaxis therefore mgt must be confident on EMA approval.
On a diff topic.. COPD market is huge with big players taking an active interest... Bronchitol is targeted for this
Swiss drugmaker Novartis said it has applied to start selling its experimental drug to treat smoker's cough — which afflicts 80 million people worldwide — after tests showed that it helped patients breathe more easily.
Novartis has carried out late-stage trials for the drug, known as NVA237, because it wants to tap into the lucrative market for respiratory drugs at a time when it is facing increasing competition for its top-selling products from generic rivals.
Analysts say Novartis could earn billions of dollars if its treatments for chronic obstructive pulmonary disease (COPD), commonly known as smoker's cough, win regulatory approval. NVA237 alone could potentially add $500 million in annual sales.
On Tuesday Novartis said NVA237, used once a day, significantly increased the functioning of lungs in patients compared with a placebo and that the first dose produced a fast response. NVA237 also enabled patients to exercise longer, it added.
Dave Morris, global development head at the Respiratory unit, said Novartis applied to the European Medicines Agency for approval at the end of August and expects a final decision from authorities some time in 2012. The drug will be marketed in the European Union as Seebri Breezhaler.
PXS Price at posting:
67.1¢ Sentiment: Hold Disclosure: Held
